Gluconolactone and pyroglutamic acid as macrosomia auxiliary diagnostic marker and application thereof

A technology of gluconolactone and pyroglutamic acid, which is applied in the field of metabolic small molecule marker combination, can solve the problems of complex experimental steps and low sensitivity, and achieves improved sensitivity and specificity, high sensitivity and specificity, and ease of use. The effect of detection

Active Publication Date: 2018-11-23
NANJING MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

NMR technology is characterized by no damage to the components to be measured, simple sample pretreatment, but low sensitivity; gas chromatography-mass spectrometr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gluconolactone and pyroglutamic acid as macrosomia auxiliary diagnostic marker and application thereof
  • Gluconolactone and pyroglutamic acid as macrosomia auxiliary diagnostic marker and application thereof
  • Gluconolactone and pyroglutamic acid as macrosomia auxiliary diagnostic marker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Embodiment 1 Research Object Selection and Grouping Basis

[0094] The present inventor collected blood samples from mothers of macrosomia patients and normal children who met the requirements from the Nanjing Maternal and Child Health Hospital Affiliated to Nanjing Medical University (see figure 1 , figure 2 ). Weigh the newborn after birth, and if the weight is equal to or greater than 4kg within 1 hour after birth, it is diagnosed as "macrosomia". In the first stage, 97 samples of pregnant women who met the requirements were randomly included, 15 of which were macrosomia; in the second stage, 30 samples of pregnant women were included, 15 of which were compared with 15 cases of macrosomia, as the blood metabolism of small molecular organisms during pregnancy of macrosomia. Screening subjects for markers. Specific sample classification criteria are as follows:

[0095] first stage screening

[0096] A total of 97 pregnant women were randomly included.

[0097] ...

Embodiment 2

[0110] Example 2 UPLC-MS metabolomics biomarker screening for macrosomia

[0111] 1. Sample pretreatment

[0112] 1. Centrifuge fresh blood during pregnancy at 3000rpm for 5min in a centrifuge, take 100μl of the supernatant and dispense it into clean 1.5ml EP tubes.

[0113] 2. Add 50 μl of serum to 50 μl of water and 300 μl of methanol (reagent A) to precipitate protein.

[0114] 3. Aspirate the supernatant, blow dry with nitrogen and then vacuum dry.

[0115] 4. Reconstitute the dry matter (Reagent D).

[0116] 2. Instrument testing

[0117] 1. Analytical instruments: UPLC Ultimate 3000system (Dionex) high-performance liquid chromatography; Q-Exactive high-resolution mass spectrometer.

[0118] 2. Liquid phase conditions:

[0119] The liquid chromatography column is a Hypersil GOLD C18 column (100mm×2.1mm, particle size 1.9μm, ThermoScientific, Germany), and the column temperature is 40°C.

[0120] The mobile phases employed were (A) 0.1% formic acid in water (reagent ...

Embodiment 3

[0132] Example 3 Stability Analysis of Small Molecules in Serum Metabolism

[0133] The method of Example 2 was used to evaluate the stability of the combined serum gluconolactone and pyroglutamic acid levels of the mother during pregnancy (the interval was 2 weeks). The results showed that the measured levels of gluconolactone and pyroglutamic acid in serum were stable ( Figure 4 ), with properties as diagnostic / monitoring markers.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the fields of analytical chemistry and clinical medicine, and discloses gluconolactone and pyroglutamic acid as a macrosomia auxiliary diagnostic marker and application thereof. The marker is serum metabolic small molecule gluconolactone and pyroglutamic acid during pregnancy. The marker is detected by a UPLC-Q exactive MS method, and has good sensitivity and specificity.The marker can be used for early diagnosis or monitoring of macrosomia, and has relatively good clinical application and promotion value.

Description

field of invention [0001] The invention belongs to the field of analytical chemistry and clinical medicine, and relates to gluconolactone and pyroglutamic acid as markers for the auxiliary diagnosis of macrosomia and their application, in particular to the detection of metabolic small molecule markers related to the occurrence of macrosomia based on UPLC-Q exact MS composition and its application. Background technique [0002] Macrosomia refers to newborns whose weight is greater than or equal to 4kg within 1 hour after birth. The occurrence of macrosomia is harmful to both mother and baby. Macrosomia is one of the important factors of dystocia, and it also increases the risk of heart abnormalities. Studies have now found that macrosomia children have a higher chance of suffering from obesity when they grow up, and will become susceptible to various diseases such as diabetes and high blood pressure. [0003] At present, the early diagnosis of macrosomia is generally based...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/72G01N33/96
CPCG01N30/02G01N30/72G01N33/96G01N2560/00G01N2570/00G01N2800/368
Inventor 陈敏健庄婷钰孙蓉丽卢婷戴礼瑞黄艳倩韦筱淇曹易之赵子平张逸王擎张鹏鹏张静胡艳辉张晓玲陆春城吴炜夏彦恺王心如
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap